News

AML is a fast-developing cancer originating in the blood and bone marrow, impacting myeloid cells that typically transform into different types of mature blood cells. REZLIDHIA is a

With this acceptance, NextPoint Therapeutics now intends to begin a first-in-human Phase I clinical trial in early 2024 analysing NPX887 in patients with solid tumours known to express

ALS is a progressive neurodegenerative disease which sees motor neurons atrophy and die, leading to loss of the ability to speak, move, eat and, ultimately even breathe. Voyager

People suffering with PNH condition have an acquired mutation that makes their red blood cells susceptible to destruction in a premature way by the complement system. A Factor

The new, first-in-class inhibitor is being assessed to treat a range of immune-mediated disorders, including lupus nephritis (LN), the most common secondary immune-mediated glomerular disease. Following the acceptance,

ELAHERE is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The deal will see ImmunoGen’s follow-on pipeline of next-generation ADCs complement the ADC platform and

The partnership has been formed through Astella’s wholly-owned subsidiary Xyphos Biosciences. They will assess the potential of antibodies, developed by Phenomic and designed for a novel tumour stroma

Schizophrenia is a long-lasting mental illness that can significantly affect a person’s thoughts, emotions, and behaviours. It impacts nearly 24 million people globally, with 2.8 million affected in

The partnership will utilise Accutar’s artificial intelligence (AI) platform and Evommune’s expertise to design and develop novel oral small molecule treatments for targets, which are the root cause